NCT05260385
To Evaluate KC1036 in the Patients with Advanced Digestive System Tumors
StatusUnknown
PhasePhase 1/2
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Recruiting
- Notable Primary completion date: Apr 30, 2024 to Oct 30, 2025
- Study completion date: Apr 30, 2025 to Dec 30, 2025
Notable Trial status: Not Yet Recruiting to Recruitingv2 Show 6 more changesShow less
- Eligibility criteria shortened, about 96 words
- Primary endpoints: 2 to 1
- Start date changed from estimate of Apr 30, 2022 to Jan 24, 2022
- Interventions: KC1036 (Drug), KC1036 (Drug) to KC1036 (Drug)
- Secondary endpoints: 7 to 8
- Study description revised
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Objective Response Rate (ORR)
Timeframe: approximately 2 year.
Secondary (8)
Progression-free survival (PFS)
Disease Control Rate (DCR)
Duration of Response (DOR)
Pharmacokinetics (PK) profile: Cmax
Pharmacokinetics (PK) profile: Tmax
Show 3 moreShow less
Pharmacokinetics (PK) profile: T1/2
Pharmacokinetics (PK) profile: AUC
Adverse events (AEs)
Arms and interventions
QD regimenExperimental
KC1036 was administered orally in 60 mg once daily, 21 days as a cycle.
BID regimenExperimental
Dose-Escalation part : KC1036 was administered orally in 20 mg BID, 30 mg BID, or 40 mg BID. Dose-Expansion part : According to the results of Dose-Escalation, an appropriate BID regimen was selected for Dose-Expansion .
Drugs: KC1036
Sites
13 sites in 1 country